J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Multiple Organ Dysfunction Syndrome in Bone Marrow Transplantation
William D. Haire,Elizabeth I. Ruby,Bruce Geoffrey Gordon,Kashinath D. Patil,L. C. Stephens,G. D. Kotulak,Elizabeth C. Reed,Julie M. Vose,Philip J. Bierman,Anne Kessinger,James O. Armitage +10 more
TL;DR: Single organ dysfunction during BMT is a marker for a systemic abnormality that has a high likelihood of progressing to MODS, similar to that seen in other critically ill patient populations, as well as a strong predictor of multiple organ dysfunction syndrome (MODS) and death.
Journal ArticleDOI
Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma.
Ying Yan,W. C. Chan,Dennis D. Weisenburger,James R. Anderson,Martin Bast,Julie M. Vose,Philip J. Bierman,James O. Armitage +7 more
TL;DR: The IPI is predictive of OS and FFS, while BM involvement with a diffuse or interstitial pattern is associated with significantly poorer OS.
Journal ArticleDOI
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
N. Nora Bennani,Matthew J. Maurer,Loretta J. Nastoupil,Michael D. Jain,Julio C. Chavez,Amanda F. Cashen,Saurabh Dahiya,Lazaros J. Lekakis,Patrick M. Reagan,Olalekan O. Oluwole,Joseph P. McGuirk,Abhinav Deol,Alison R. Sehgal,Andre Goy,Brian T. Hill,Khoan Vu,Charalambos Andreadis,Javier Munoz,Aaron P. Rapoport,Julie M. Vose,David B. Miklos,Frederick L. Locke,Sattva S. Neelapu,Yi Lin +23 more
TL;DR: This report reports here the real-world experience of 17 pts treated with axi-cel who had a history of secondary CNS involvement or had active CNS disease at time of CAR T infusion, and found the ITT best overall response rates and event-free survival.
Journal ArticleDOI
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
Anamarija M. Perry,Teresa Cardesa-Salzmann,Paul N. Meyer,Luis Colomo,Lynette M. Smith,Kai Fu,Timothy C. Greiner,Jan Delabie,Randy D. Gascoyne,Lisa M. Rimsza,Elaine S. Jaffe,German Ott,Andreas Rosenwald,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Louis M. Staudt,Joseph M. Connors,Laurie H. Sehn,Julie M. Vose,Armando López-Guillermo,Elias Campo,Wing C. Chan,Dennis D. Weisenburger +23 more
TL;DR: A new biologic prognostic model based on immunohistochemistry that delineates 2 groups of patients, 1 with a low biologic score and good survival and the other with a high score and poor survival, could be used with the International Prognostic Index to stratify patients for novel or risk-adapted therapies.
Journal ArticleDOI
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
Sonali M. Smith,James Godfrey,Kwang Woo Ahn,Alyssa DiGilio,Sairah Ahmed,Vaibhav Agrawal,Veronika Bachanova,Ulrike Bacher,Ulrike Bacher,Asad Bashey,Javier Bolaños-Meade,Mitchell S. Cairo,Andy I. Chen,Saurabh Chhabra,Edward A. Copelan,Parastoo B. Dahi,Mahmoud Aljurf,Umar Farooq,Siddhartha Ganguly,Mark P. Hertzberg,Leona Holmberg,David J. Inwards,Abraham S. Kanate,Reem Karmali,Vaishalee P. Kenkre,Mohamed A. Kharfan-Dabaja,Andreas K. Klein,Hillard M. Lazarus,Matthew Mei,Alberto Mussetti,Taiga Nishihori,Praveen Ramakrishnan Geethakumari,Ayman Saad,Bipin N. Savani,Harry C. Schouten,Nirav N. Shah,Alvaro Urbano-Ispizua,Ravi Vij,Julie M. Vose,Anna Sureda,Mehdi Hamadani +40 more
TL;DR: Early treatment failure in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high‐risk group of patients with an expected 5‐year overall survival rate of approximately 50%.